

## PEER-REVIEW REPORT

**Name of journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 81156

**Title:** Successful treatment of GPA using tocilizumab combined with glucocorticoids: A case report and literature review

**Provenance and peer review:** Unsolicited Manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 06412662

**Position:** Peer Reviewer

**Academic degree:** MD

**Professional title:** Academic Research, Doctor

**Reviewer's Country/Territory:** Nepal

**Author's Country/Territory:** China

**Manuscript submission date:** 2022-10-27

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2022-11-13 06:19

**Reviewer performed review:** 2022-11-15 06:34

**Review time:** 2 Days

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** bpgoffice@wjgnet.com  
<https://www.wjgnet.com>

<b>Peer-reviewer statements</b>	Peer-Review: [ <input checked="" type="checkbox"/> ] Anonymous [ <input type="checkbox"/> ] Onymous Conflicts-of-Interest: [ <input type="checkbox"/> ] Yes [ <input checked="" type="checkbox"/> ] No
-------------------------------------	---

#### **SPECIFIC COMMENTS TO AUTHORS**

written with good quality and case specific

## PEER-REVIEW REPORT

**Name of journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 81156

**Title:** Successful treatment of GPA using tocilizumab combined with glucocorticoids: A case report and literature review

**Provenance and peer review:** Unsolicited Manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 03715067

**Position:** Peer Reviewer

**Academic degree:** MD, PhD

**Professional title:** Doctor, Professor

**Reviewer's Country/Territory:** France

**Author's Country/Territory:** China

**Manuscript submission date:** 2022-10-27

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2022-11-10 06:11

**Reviewer performed review:** 2022-11-19 15:15

**Review time:** 9 Days and 9 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input checked="" type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input checked="" type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input checked="" type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No

<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous
	Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

## SPECIFIC COMMENTS TO AUTHORS

I reviewed the case report titled «Successful treatment of granulomatosis with polyangiitis using tocilizumab combined with glucocorticoids: A case report and literature review ». Major comments : It is poorly written, the english is very approxymative : therefore it is difficult to follow ! It is NOT possible that there is a single author !!! Indeed rheumatologist, immunologist, pathologist were involved : HOW can they have been skipped from being co-authors ??? The titled is misleading : I could NOT find the literature review ! There SHOULD be a Table summarizing the use of Tocilizumab in ANCA-associated vasculitis. Minor comments : It is stated « B lymphocyte antigen 4.1% (10-15%), CD4 35.1% (25.8-41.6%), CD8 52.2% (18.1-29.6%), and etc » : please which CD was assessed for B lymphocytes ? In addition, lymphocyte substest should be given either in G/L or in /mm3. Cyclophosphamide was discontinued, and the hormone doses were reduced : what does it mean ? It is stated « However, the G test was positive twice, while the GM test was negative. The vasculitis was considered to be controlled, but the pulmonary fungal infection persisted. Dose reduction was obtained, and methylprednisolone 6 mg/d was administered. Cyclophosphamide was replaced with TW for immunosuppression... » : what do G, GM, TW ??? « EB DNA was 5.09E+4↑copies/ml. Negative results were obtained for the pathological examination of tracheal lavage fluid, and TORCH test analysis ... » : it should read EBV instead of EB ; what does T After dose reduction of the hormones, etc ... : what does hormones mean ???